In:
Acta Haematologica, S. Karger AG, Vol. 101, No. 3 ( 1999), p. 119-123
Abstract:
To investigate the clinical implications of germline Cµ transcription, the splice region between the 3′ end of the enhancer and the first exon of immunoglobulin germline μ was analyzed by RT-PCR in 63 samples from 59 patients with leukemia. Immunophenotypes of 33 samples from patients with acute leukemia were analyzed using a panel of these monoclonal antibodies: anti-immature/stem cell (HLA-DR, CD34); anti-mature myeloid (CD33, CD15); anti-T lymphoid (CD2, CD3, CD5, CD7, CD8), and anti-B lymphoid (CD10, CD19, CD20). Of the 63 samples, 33 (52%) contained germline Cµ transcripts: 2/2 patients with chronic lymphocytic leukemia; 17/26 (65.4%) patients with acute myeloblastic leukemia; all 4 patients with chronic myelogenous leukemia in blast crisis and 1 in accelerated phase; 9/12 patients with acute lymphocytic leukemia. A clear correlation between germline transcripts and HLA-DR expression was observed among germline-positive cases (p 〈 0.01). Cµ expression and response to therapy clearly indicated that germline-µ-positive leukemia patients responded poorly to chemotherapy and had a worse clinical prognosis compared with Cµ-negative patients (p 〈 0.01). After two courses of chemotherapy, 7/9 Cµ-negative patients achieved complete remission compared to only 7/29 Cµ-positive patients (p 〈 0.01). We conclude that the gene-regulating immunoglobulin germline Cµ may be amplified in myeloid and B-lymphoid cells during leukemogenesis. Such genetic changes may be correlated with cellular terminal differentiation injury, resistance to chemotherapy and uncontrolled malignant cell proliferation.
Type of Medium:
Online Resource
ISSN:
0001-5792
,
1421-9662
Language:
English
Publisher:
S. Karger AG
Publication Date:
1999
detail.hit.zdb_id:
1481888-7
detail.hit.zdb_id:
80008-9
Permalink
